Investigation into the effect of microsampling on mouse fetuses and pregnant mice in the embryofetal development

Terri Mitchard1, Sarah Kirk2, Claire Grant1

  • 1AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom.

Insights

Taking three 32μL blood microsamples during mouse embryofetal development studies has no adverse effects on maternal health or fetal development. This method reduces the need for satellite animals in toxicokinetic studies.

Area of Science:

  • Reproductive toxicology
  • Developmental toxicology
  • Animal welfare in research

Background:

  • Reducing animal usage in toxicological studies is crucial.
  • Embryofetal development (EFD) studies often require significant animal numbers.
  • Microsampling techniques offer potential for reducing animal use.

Purpose of the Study:

  • To investigate the effects of microsampling on maternal health and fetal development in mice.
  • To evaluate the impact of sampling frequency (3 vs. 6 times) and associated procedures (warming, handling) on study outcomes.
  • To determine if a 3-microsample regimen is viable for generating toxicokinetic profiles with reduced animal numbers.

Main Methods:

  • Mouse embryofetal development (EFD) study design.
  • Collection of 32μL blood microsamples on gestation day 16.
  • Evaluation of maternal body weight gain and fetal weights on gestation day 18.
  • Comparison of 3 sampling occasions versus 6 sampling occasions, with and without warming/handling.

Main Results:

  • Transient reduction in maternal body weight gain observed with warming and handling, with or without sampling.
  • Fetal weights were reduced on gestation day 18 following 6 sampling occasions (with/without handling), but not with 3 sampling occasions.
  • No permanent adverse effects on maternal health or toxicologically significant effects on fetal development were found with the 3-microsample regimen.

Conclusions:

  • A regimen of taking 3 microsamples of 32μL in mouse EFD studies does not cause permanent adverse effects.
  • This microsampling approach can be used to generate composite toxicokinetic profiles with fewer animals (e.g., 6 main test animals).
  • Standardized sampling procedures across groups are essential for the validity of this reduced-animal approach.

Related Concept Videos